Explanation of whether patients without genetic mutations can take adagrasib (Krazati)

Adagrasib (Krazati) is an oral KRAS G12C inhibitor and belongs to a new generation of targeted therapy drugs. Its mechanism of action is to specifically target the abnormal protein after the KRAS geneG12C mutation, blocking cancer cell proliferation signaling pathways, thereby inhibiting tumor growth. The drug has been approved in Europe and the United States for the treatment of patients with locally advanced or metastatic non-small cell lung cancer carrying KRAS G12C mutations, and its efficacy in other tumor types is also being studied. Its clinical use strictly relies on genetic testing results.

For patients who do not have theKRAS G12C mutation, taking adagrasib is generally ineffective. Because the target of the drug is clear, if there are no corresponding mutations in cancer cells, the drug cannot bind to the abnormal protein, and it will not be able to inhibit tumors. Both clinical trials and real-world data show that only patients who are confirmed to be positive for the KRAS G12C mutation through genetic testing can benefit from this type of targeted therapy. Therefore, unauthorized use of adagrasib is not recommended for patients without genetic mutations.

If adagrasib is used without mutations, it may not only fail to achieve the expected anti-tumor effect, but may also cause drug-related adverse reactions, such as diarrhea, nausea, fatigue, abnormal liver function and other side effects. At the same time, targeted drugs are expensive and the economic burden of long-term medication is not small. In the absence of corresponding molecular targets, blindly taking such drugs will waste resources and may delay other more appropriate treatment options, such as chemotherapy, immunotherapy or other targeted drugs.

Therefore, the key to whether adagrasib is suitable for use lies in the presence of KRAS G12C mutation. Patients should undergo formal molecular pathology testing before starting treatment. After the mutation status is clear, a professional oncologist will formulate an individualized treatment plan. For patients without mutations, they should choose a more appropriate treatment method under the guidance of a doctor instead of purchasing targeted drugs on their own. Scientific and accurate diagnosis and medication are the prerequisites for ensuring treatment effects and patient safety.

Reference materials:https://www.drugs.com/